GLP-1 RAs in Chronic Migraine
Investigators evaluate health care utilization and treatment patterns vs topiramate in an active-comparator study.
By
Kathryn Wighton
March 3, 2026
Clinical Scorecard: GLP-1 RAs in Chronic Migraine
At a Glance
Category Detail
Condition Chronic Migraine Key Mechanisms GLP-1 receptor agonists may stabilize disease burden and reduce migraine-related healthcare utilization. Target Population Adults with chronic migraine (defined as headache on 15 or more days per month for at least 3 months). Care Setting Outpatient settings, with data derived from emergency department and hospitalization records.
Key Highlights
GLP-1 RAs associated with lower emergency department visits (24% vs 26% for topiramate). Reduced hospitalizations and nerve block procedures in patients using GLP-1 RAs. Lower initiation rates of additional preventive medications among GLP-1 RA users. Study based on a real-world cohort of 10,997 patients per treatment group. No randomized controlled trials have assessed the preventive efficacy of GLP-1 RAs in migraine. Guideline-Based Recommendations
Diagnosis
Chronic migraine defined as headache on 15 or more days per month for at least 3 months. Management
Consider GLP-1 RAs as a potential option for chronic migraine management. Monitoring & Follow-up
Monitor for changes in emergency department visits and hospitalization rates. Risks
Unmeasured factors may influence outcomes, including weight loss and lifestyle changes. Patient & Prescribing Data
Adults with chronic migraine initiating treatment.
GLP-1 RAs may lead to lower use of acute migraine treatments and additional preventive therapies.
Clinical Best Practices
Evaluate patient history and comorbidities before initiating GLP-1 RAs. Monitor patient outcomes regularly to assess efficacy and safety. Consider lifestyle factors that may impact migraine frequency and severity. References
